Investigational Drug May Combat Brain Tumors By Targeting Cancer Cells' Fat Production
The oral drug is currently being evaluated in phase I clinical trials for Parkinson’s disease.
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
Stay up to date with progresses and for future eligibility to participate in our program
Parkinson's disease (PD) is a neurodegenerative and movement disorder affecting dopamine-producing neurons in a brain region called the substantia nigra.
Currently, there are no cures for Parkinson's disease.Overview of human induced pluripotent stem cells personalized cell replacement therapy for Parkinson’s Disease
For several decades the Massachusetts General Hospital Department of Neurosurgery and Department of Neurology have led in patient care for those with Parkinson's disease and advancing clinical research to develop new treatments with the hope of creating a cure.
Mass General physicians, in collaboration with researchers from McLean hospital, recently reported on a patient that underwent a novel neurosurgical technique to treat their Parkinson's disease, published in the New England Journal of Medicine. In this study, led by Jeffrey S. Schweitzer, MD, PhD, neurosurgeon in the Department of Neurosurgery, Todd M. Herrington, MD, PhD, director of the Deep Brain Stimulation Program in the Department of Neurology, and Bob S. Carter, MD, PhD, chief of Neurosurgery and in collaboration with Kwang-Soo Kim, PhD, director of the Molecular Neurobiology Laboratory at McLean Hospital, clinicians surgically transplanted dopamine neurons derived from the patient's own stem cells into the brain. The patient reported improved motor function in daily life and experienced no adverse effects, but larger, randomized controlled trials will be necessary to demonstrate efficacy (read the press release).
Below are patient resources on Parkinson's disease related centers at Mass General and research news items.
You can also fill out a subscription form, which will allow patients to stay up to date with our cell therapy treatment advancements.
Subscribe for Cell Therapy Updates
First-In-Human Therapy with Stem Cell–derived Dopaminergic Progenitor Cells for Parkinson's Disease
Patient-Derived Dopamine Neurons Show Promise in Parkinson’s Treatment
Learn about our recent developments in stem-cell therapy, research and news.
Contact Sarah Gaylord, director of Development (sgaylord@partners.org) to make a gift to Parkinson’s cell therapy
Mass General is the #1 research hospital in America, with a large percentage of that dedicated to Neuro-related diseases.
The oral drug is currently being evaluated in phase I clinical trials for Parkinson’s disease.
The investigational technology has an encouraging safety profile and should continue to be studied for its potential to help people with paralysis.
Topline results in adults with amyotrophic lateral sclerosis (ALS) from Regimen C evaluating CMN-Au8, developed by Clene Nanomedicine, Inc., a suspension of gold nanocrystals to enhance neuronal energy production and utilization
The HEALEY ALS Platform Trial led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) today announced topline results from Regimen C evaluating CMN-Au8, developed by Clene Nanomedicine, Inc.
Technology looks for pieces of tumor cells’ genetic material that are circulating in the blood.
A Mass General study has found that resilience to delirium after elective surgery is associated with the thickness of a frontal region of the brain.
Please contact Sarah Gaylord, director of development for the Department of Neurosurgery at Mass General, if you have questions about making a gift to support Parkinson’s Cell Therapy research at Mass General.